Methylation pharmacogenetics: thiopurine methyltransferase as a model system

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Biotechnology

Background:

• Methyl conjugation is a critical biotransformation pathway for many xenobiotics.
• Pharmacogenetic variations in methyltransferase enzymes influence drug efficacy and toxicity.
• Thiopurine methyltransferase (TPMT) serves as a model enzyme for studying methyltransferase pharmacogenetics.

Purpose of the Study:

• To explore the role of TPMT genetic polymorphism in thiopurine drug metabolism.
• To investigate the utility of animal models in studying TPMT pharmacogenetics.
• To understand how inherited differences in methylation affect drug response.

Main Methods:

• Studied TPMT enzyme activity in human red blood cells (RBCs).
• Examined genetic polymorphism in TPMT activity across different human tissues and inbred mouse strains.
• Investigated other RBC methyltransferases, including thiol methyltransferase, catechol O-methyltransferase, and histamine N-methyltransferase.

Main Results:

• TPMT activity in RBCs reflects genetic polymorphism affecting enzyme activity in other tissues.
• Inherited low TPMT activity increases risk of myelotoxicity from thiopurine drugs.
• Inbred mice exhibit genetic regulation of TPMT activity, serving as a relevant animal model.
• Other methyltransferases in RBCs are also heritably regulated, contributing to drug metabolism variability.

Conclusions:

• TPMT genetic polymorphism is a significant factor in thiopurine drug response and toxicity.
• Animal models are valuable for studying the consequences of inherited differences in TPMT activity.
• Understanding methyltransferase pharmacogenetics can predict individual variations in drug biotransformation, toxicity, and therapeutic effects.